8-KLeadership ChangesExhibits & Filings

BOSTON SCIENTIFIC CORP 8-K Report, Executive Changes (Nov 22, 2016)

Filed November 22, 2016For Securities:BSX

Summary

This Form 8-K filing by Boston Scientific Corporation (BSX) details the approval of key compensation plans for the upcoming 2017 fiscal year. The company's Board of Directors, on the recommendation of its Compensation Committee, has approved the 2017 Annual Bonus Plan and two new performance share programs: the 2017 Total Shareholder Return Performance Share Program (2017 TSR PSP) and the 2017 Free Cash Flow Performance Share Program (2017 FCF PSP). These plans are designed to align executive compensation with company performance and shareholder interests. The 2017 Annual Bonus Plan ties cash incentives to adjusted earnings per share and global sales, with specific performance thresholds and a cap on the bonus pool. The TSR PSP links awards to the company's stock performance relative to the S&P 500 Healthcare Index over three years, while the FCF PSP incentivizes the achievement of free cash flow targets within a one-year period. Importantly, awards under these programs are subject to recoupment policies, including provisions for misconduct, financial restatements, and Dodd-Frank Act clawbacks, underscoring a focus on accountability and robust corporate governance.

Key Highlights

  • 1Approval of the 2017 Annual Bonus Plan, which is substantially similar to the 2016 plan.
  • 2The 2017 Annual Bonus Plan is based on achieving corporate-level performance goals for adjusted earnings per share and global sales (on a constant currency basis).
  • 3A floor of 50% and a ceiling of 150% of the Aggregate Annual Target for the bonus pool, with a specific cap if global sales performance is below 97% of the goal.
  • 4Board discretion to adjust bonuses based on quality objectives and performance of quality systems.
  • 5Adoption of two new long-term incentive programs for 2017: the Total Shareholder Return Performance Share Program (2017 TSR PSP) and the Free Cash Flow Performance Share Program (2017 FCF PSP).
  • 6The 2017 TSR PSP measures performance against the S&P 500 Healthcare Index over a three-year period.
  • 7The 2017 FCF PSP incentivizes the achievement of free cash flow targets against the company's financial plan over a one-year period.
  • 8All approved plans include recoupment policies for executive misconduct, financial restatements, and Dodd-Frank Act clawbacks.

Frequently Asked Questions

The 2017 Annual Bonus Plan's bonus pool is primarily based on the achievement of corporate-level performance goals for adjusted earnings per share and global sales (measured on a constant currency basis).

For 2017, Boston Scientific is introducing two performance share programs: the 2017 Total Shareholder Return Performance Share Program (2017 TSR PSP) and the 2017 Free Cash Flow Performance Share Program (2017 FCF PSP). These programs aim to align executive pay with shareholder value creation and critical business objectives.

Awards to certain executive officers under both the 2017 Annual Bonus Plan and the 2017 Performance Share Programs are subject to the company's recoupment policy. This policy allows the company to seek reimbursement of bonuses or performance share units in cases of executive misconduct, gross dereliction of duty leading to material harm, financial restatements that would have reduced awards, or as required by clawback provisions under laws like the Dodd-Frank Act.

The performance period for the 2017 TSR PSP is three years, beginning on January 1, 2017, and ending on December 31, 2019. Performance is measured by comparing Boston Scientific's Total Shareholder Return (TSR) against that of other companies in the S&P 500 Healthcare Index.